Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6459262 | 1.00 | ACE (0.49) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL2385485 | 0.92 | ITGA4 (0.49) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL2904541 | 0.91 | JAK2 (0.42) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL2386632 | 0.90 | ITGA4 (0.45) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL5030051 | 0.90 | ITGA4 (0.45) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL7389438 | 0.89 | ITGA4 (0.55) | ACEITGA4ITGB7CTSSAKT1 | |
| SCHEMBL2907748 | 0.88 | GPR132 (0.51) | ACEPPARGMMEACE2 | |
| SCHEMBL2388324 | 0.87 | ATM (0.47) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL2385034 | 0.87 | ITGA4 (0.45) | ACEITGA4ITGB7CTSSCTSL | |
| SCHEMBL2385950 | 0.87 | ITGA4 (0.47) | ACEITGA4ITGB7CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101547893-B | Method for collection of L-biphenylalanine compound salt, and method for collection of biphenylalanine ester compound using the same | SUMITOMO CO LTD | 2012-07-25 | — | — | CN | claimed |
| CN-101547893-A | Method for collection of L-biphenylalanine compound salt, and method for collection of biphenylalanine ester compound using the same | SUMITOMO CHEMICAL CO (JP) | 2009-09-30 | — | — | CN | claimed |
| CN-101547893-B | Method for collection of L-biphenylalanine compound salt, and method for collection of biphenylalanine ester compound using the same | SUMITOMO CO LTD | 2012-07-25 | — | — | CN | disclosed |
| US-8017378-B2 | Method for production of optically active biphenylalanine compound or salt or ester thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-09-13 | — | — | US | disclosed |
| EP-1980622-B1 | METHOD FOR PRODUCTION OF AN OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | SUMITOMO CHEMICAL CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| CN-101547893-A | Method for collection of L-biphenylalanine compound salt, and method for collection of biphenylalanine ester compound using the same | SUMITOMO CHEMICAL CO (JP) | 2009-09-30 | — | — | CN | disclosed |
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| WO-2008144728-A1 | CONJUGATES WHICH BIND A BLOOD PROTEIN SUCH AS HUMAN SERUM ALBUMIN AND METHODS OF USING THE SAME IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2008-11-27 | — | — | WO | disclosed |
| EP-1980622-A1 | METHOD FOR PRODUCTION OF OPTICALLY ACTIVE BIPHENYLALANINE COMPOUND OR SALT OR ESTER THEREOF | Sumitomo Chemical Company, Limited (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1742907-A4 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-02 | — | — | EP | disclosed |
| CN-1984928-A | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | AVANIR PHARMACEUTICALS (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
| WO-2005123770-A1 | MEDIATORS OF REVERSE CHOLESTEROL TRANSPORT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | AVANIR PHARMACEUTICALS (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
| EP-1150565-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION bioscience AG (DE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000045635-A1 | THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | ACE 2658/4885ITGA4 2189/4885ITGB7 2872/4885 |
| US-20090011475-A1 | Method For Production of Optically Active Biphenylalanine Compound or Salt or Ester Thereof | DNPEP, APEH, PAH | ACE 31/4885ITGA4 4819/4885ITGB7 4625/4885 |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | ACE 10/4885ITGA4 2567/4885ITGB7 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.